Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.74 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.67 |
| ▸ | INSR | P06213 | 3/20 | 0.67 |
| ▸ | IGF1R | P08069 | 3/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.67 |
| ▸ | ROS1 | P08922 | 1/20 | 0.67 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.67 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.62 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29216391 | 0.96 | EGFR (0.72) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL30141622 | 0.96 | EGFR (0.72) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24327081 | 0.90 | EGFR (0.73) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL26778364 | 0.89 | ALK (0.77) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24351525 | 0.87 | EGFR (0.75) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24328341 | 0.87 | EGFR (0.67) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL30871981 | 0.87 | EGFR (0.75) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL30223046 | 0.86 | EGFR (0.61) | EGFRALKINSRIGF1R | |
| SCHEMBL21846992 | 0.85 | EGFR (1.00) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL29661303 | 0.84 | ALK (0.75) | EGFRALKINSRIGF1RAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171416-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-29 | — | — | US | claimed |
| US-20240352000-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2024-10-24 | — | — | US | claimed |
| EP-4371983-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2024-05-22 | — | — | EP | claimed |
| US-20250171416-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-29 | — | — | US | disclosed |
| US-20240352000-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2024-10-24 | — | — | US | disclosed |
| EP-4371983-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2024-05-22 | — | — | EP | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 13/4885INSR 82/4885 |
| US-20240352000-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | WEE2, WEE1, ERBB2 | EGFR 6/4885ALK 1560/4885INSR 2235/4885 |
| US-20250171416-A2 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | WEE2, WEE1, ERBB2 | EGFR 6/4885ALK 1560/4885INSR 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.